遺伝子治療市場は、2024年から2034年にかけて20.4%のCAGRで成長し、市場価値は668億ドルに達すると予測されます。この成長は、CRISPRやウイルスベクター技術などの遺伝子工学技術の進歩によって推進されており、遺伝子治療の精度と有効性が向上しています。遺伝性疾患の有病率の増加と標的療法の需要が、市場への関心を高めています。官民両セクターからの研究開発への多額の投資が、遺伝子治療のイノベーションを推進し、パイプラインを拡大しています。規制当局の承認と支援政策が、市場の成長をさらに推進します。遺伝子治療の未来は、がんや希少疾患の治療への応用の増加、送達方法の改善、治療費の削減の可能性など、すべてが市場の拡大と個別化医療の進歩に貢献していることから、有望視されています。
目次
Table of Content
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Gene Therapy Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Gene Therapy Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Gene Therapy Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porter's Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Gene Therapy Market
10.1. Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Gene Therapy Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Type
11.3.1.1. Gene Silencing
11.3.1.1.1. By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2. Gene Augmentation
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2. Market Share (%) 2024A-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.3. Cell Replacement
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2. Market Share (%) 2024A-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.4. Other Therapies
11.3.1.4.1. By Value (USD Million) 2024A-2034F
11.3.1.4.2. Market Share (%) 2024A-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Vector
11.3.2.1. Viral Vectors
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2. Market Share (%) 2024A-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Non-Viral Vectors
11.3.2.2.1. By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3. By Therapeutic Area
11.3.3.1. Neurology
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2. Market Share (%) 2024A-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Oncology
11.3.3.2.1. By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Hepatology
11.3.3.3.1. By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Other Therapeutic Areas
11.3.3.4.1. By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4. By Delivery Method
11.3.4.1. In-Vivo
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2. Market Share (%) 2024A-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Ex-Vivo
11.3.4.2.1. By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5. By Route of Administration
11.3.5.1. Intravenous
11.3.5.1.1. By Value (USD Million) 2024A-2034F
11.3.5.1.2. Market Share (%) 2024A-2034F
11.3.5.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.2. Other Routes of Administration
11.3.5.2.1. By Value (USD Million) 2024A-2034F
11.3.5.2.2. Market Share (%) 2024A-2034F
11.3.5.2.3. Y-o-Y Growth (%) 2024A-2034F
12. North America Gene Therapy Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2. By Vector
12.3.3. By Therapeutic Area
12.3.4. By Delivery Method
12.3.5. By Route of Administration
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Gene Therapy Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2. By Vector
13.3.3. By Therapeutic Area
13.3.4. By Delivery Method
13.3.5. By Route of Administration
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Gene Therapy Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2. By Vector
14.3.3. By Therapeutic Area
14.3.4. By Delivery Method
14.3.5. By Route of Administration
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Gene Therapy Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2. By Vector
15.3.3. By Therapeutic Area
15.3.4. By Delivery Method
15.3.5. By Route of Administration
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Gene Therapy Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Type
16.3.2. By Vector
16.3.3. By Therapeutic Area
16.3.4. By Delivery Method
16.3.5. By Route of Administration
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Novartis
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.2. Spark Therapeutics
18.3. Regenxbio
18.4. Gilead Sciences
18.5. CRISPR Therapeutics
18.6. Vertex Pharmaceuticals
18.7. Pfizer
18.8. Bluebird Bio
18.9. Bayer AG
18.10. AstraZeneca
18.11. Sangamo Therapeutics
18.12. Merck KGaA
18.13. Astellas Pharma
18.14. Takeda Pharmaceutical
18.15. BioMarin Pharmaceutical
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
